OnKure Therapeutics (OKUR) Research & Development (2020 - 2026)

OnKure Therapeutics (OKUR) has reported Research & Development for 7 consecutive years, with $12.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development changed 0.02% year-over-year to $12.6 million; the trailing twelve-month figure through Jun 2026 stood at $47.0 million (down 6.29% YoY), and the FY2025 full-year result was $48.3 million, up 10.2% from the prior year.
• Research & Development climbed to $12.6 million in Q2 2026 per OKUR's latest filing, from $11.7 million in the prior quarter.
• Across five years, Research & Development topped out at $14.4 million in Q2 2023 and bottomed at -$6.9 million in Q4 2023.
• Historically, Research & Development has averaged $10.3 million across 5 years, with a median of $10.9 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Research & Development tumbled 166.56% in 2023, then soared 308.31% in 2024.
• Over 5 years, Research & Development stood at $10.4 million in 2022, then sank by 166.56% to -$6.9 million in 2023, then jumped by 308.31% to $14.4 million in 2024, then fell by 25.35% to $10.7 million in 2025, then rose by 17.64% to $12.6 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $12.6 million, $11.7 million, and $10.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.